# ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.

> **NCT02681523** · PHASE2 · TERMINATED · sponsor: **Imperial College London** · enrollment: 8 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT02681523
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10-28
- **Primary completion:** 2018-07-24
- **Final completion:** 2018-07-24
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Slow patient recruitment
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02681523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02681523, "ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02681523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*